Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Citius Pharmaceuticals Inc. (CTXR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.58, with a market capitalisation of $15.73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.47 to $2.19. This page covers its latest market performance, valuation, price trends and company information.
$15.73M | |
$0.56 | |
$137.25 | |
$0.47 | |
$0.56 | |
103.00 | |
540.20K | |
-- | |
$2.19 | |
$0.47 | |
-- | |
-- |
Citius Pharmaceuticals Inc. (CTXR) is trading at $0.58 in pre-market trading as of 2026-09-16 10:04:00, up 3.37% ($0.02) from the previous close of $0.56
Pre-market trading shows how investors are pricing CTXR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Citius Pharmaceuticals Inc. (CTXR) moved from $0.59 to $0.58, representing a decline of 1.48% ($0.01).
The stock traded between $0.56 and $0.62 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 192.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.4%
CTXR is currently trading at $0.58, placing it 6.4% of the way from its 52-week low of $0.47 to its 52-week high of $2.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Citius Pharmaceuticals Inc. (CTXR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.